Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Madrigal PharmaceuticalsMDGL -5.23%31 EV-to-OCF is -52.13 as of Aug. 02, 2026. GuruFocus rates MDGL with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 1,410 Biotechnology companies, Madrigal Pharmaceuticals ranks better than 92.55% on this metric.
The historical rank and industry rank for Madrigal Pharmaceuticals's EV-to-OCF or its related term are showing as below:
MDGL'
s EV-to-OCF Range Over the Past 10 Years
Min: -79.1 Med: -25.56 Max: -8.03
Current: -52.13
During the past 13 years, the highest EV-to-OCF of Madrigal Pharmaceuticals was -8.03. The lowest was -79.10. And the median was -25.56.
MDGL's EV-to-OCF is ranked better than 92.55% of 1410
companies
in the Biotechnology industry
Industry Median: -3.23
vs MDGL: -52.13
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Madrigal Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Madrigal Pharmaceuticals's share price for today is $467.32.
Madrigal Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.890.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Madrigal Pharmaceuticals EV-to-OCF Related Terms
Madrigal Pharmaceuticals EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Madrigal Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Madrigal Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Madrigal Pharmaceuticals's EV-to-OCF falls into.
Madrigal Pharmaceuticals's current Enterprise Value is $10,306 Mil.
Madrigal Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-198 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Madrigal Pharmaceuticals (MDGL) has a EV-to-OCF of -52.13 as of Aug. 02, 2026. According to the industry distribution chart, Madrigal Pharmaceuticals ranks #105 out of 1410 companies in the Biotechnology industry, placing it in the top 7.4%.
Is Madrigal Pharmaceuticals' EV-to-OCF too high?
Madrigal Pharmaceuticals' current EV-to-OCF is -52.13. Based on the distribution chart, Madrigal Pharmaceuticals ranks #105 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Madrigal Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Madrigal Pharmaceuticals' EV-to-OCF compare to AXSM and ARWR?
According to the Biotechnology industry distribution chart, Madrigal Pharmaceuticals ranks #105 out of 1410 companies for EV-to-OCF. This places Madrigal Pharmaceuticals in the top 7% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Madrigal Pharmaceuticals's current EV-to-OCF is -52.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madrigal Pharmaceuticals stock overvalued right now?
Madrigal Pharmaceuticals (MDGL) has a current EV-to-OCF of -52.13. The current EV-to-OCF is -52.13. Madrigal Pharmaceuticals' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Madrigal Pharmaceuticals (MDGL), the current EV-to-OCF is -52.13 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
31GF Score
Get the complete analysis for MDGL
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDGL has been successfully added to your 
